Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 1, 2010, Pages

  Yang, Jong In ^a   Yoon, Jung Hwan ^a   Bang, Yung Jue ^a   Lee, Sung Hee ^a   Lee, Soo Mi ^a   Byun, Hee Jin ^a   Myung, Sun Jung ^a   Kim, Won ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Enzastaurin; Liver fibrosis; Pravastatin

Indexed keywords

4',6 DIAMINDINO 2 PHENYLINDOLE; ALPHA SMOOTH MUSCLE ACTIN; BIOTIN; CARBON TETRACHLORIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; ENZASTAURIN; INDOLE DERIVATIVE; PRAVASTATIN; THIOACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER FIBROSIS; MALE; MITOCHONDRION; MORPHOMETRICS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL;

ANIMALS; APOPTOSIS; BODY WEIGHT; CARBON TETRACHLORIDE; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; MITOCHONDRIA; ORGAN SIZE; PRAVASTATIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; THIOACETAMIDE;

EID: 73549090321     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00299.2009     Document Type: Article

References (35)

1. Aprigliano I, Dudas J, Ramadori G, Saile B. Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells. Liver Int 28: 546-557, 2008.
2. Bao N, Minatoguchi S, Kobayashi H, Yasuda S, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y, Arai M, Nishigaki K, Takemura G, Fujiwara T, Fujiwara H. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J 71: 1622-1628, 2007.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218, 2005.
4. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 46: 443-446, 2000.
5. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24: 4092-4099, 2006.
6. Chang ML, Yeh CT, Chang PY, Chen JC. Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol 11: 4167-4172, 2005.
7. Chilakapati J, Korrapati MC, Hill RA, Warbritton A, Latendresse JR, Mehendale HM. Toxicokinetics and toxicity of thioacetamide sulfoxide: a metabolite of thioacetamide. Toxicology 230: 105-116, 2007.
8. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132: 1937-1946, 2007.
9. Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Bolognini L, Feliciangeli G, Jezequel AM, Orlandi F, Benedetti A. Intracellular pathways mediating Na+/H+ exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology 116: 1155-1166, 1999.
10. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
11. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 38, Suppl 1: S38-S53, 2003.
12. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615, HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469, 2005.
13. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36: 12-21, 2002.
14. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117: 539-548, 2007.
15. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102: 538-549, 1998.
16. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27: 173-179, 1999.
17. Jaster R, Brock P, Sparmann G, Emmrich J, Liebe S. Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor lovastatin. Biochem Pharmacol 65: 1295-1303, 2003.
18. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796-1807, 2003.
19. Kim W, Yoon JH, Kim JR, Jang IJ, Bang YJ, Kim YJ, Lee HS. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol 64: 497-507, 2009.
20. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 97: 52C-60C, 2006.
21. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286: F46-F57, 2004.
22. Louneva N, Huaman G, Fertala J, Jimenez SA. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 54: 1298-1308, 2006.
23. Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 54: 1-49, 2006.
24. Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. J Pharmacol Exp Ther 330: 276-282, 2009.
25. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42, Suppl 1: S22-S36, 2005.
26. Ramm GA, Li L, Britton RS, O'Neill R, Bacon BR. Effect of protein kinase C activation and inhibition on rat hepatic stellate cell activation. Dig Dis Sci 48: 790-796, 2003.
27. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25: 1741-1746, 2007.
28. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38: 564-572, 2003.
29. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 33: 1164-1171, 2006.
30. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71-105, 2006.
31. Svegliati-Baroni G, Ridolfi F, Di Sario A, Saccomanno S, Bendia E, Benedetti A, Greenwel P. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology 33: 1130-1140, 2001.
32. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB. Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 159: 220-227, 1999.
33. Tanaka K, Honda M, Takabatake T. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 31: 360-364, 2004.
34. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151, 2005.
35. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, Fukui H. Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res 27: 51-56, 2003.